Inozyme Acquired by BioMarin Pharmaceutical | Healthcare M&A Deal

BioMarin Pharmaceutical has completed the acquisition of Inozyme, a pharmacy business in California, for $270 million. Inozyme focuses on rare disease therapeutics, supporting BioMarin Pharmaceutical acquisitions aimed at expanding its pipeline in healthcare deals CA. The add on acquisition strengthens BioMarin’s strategic acquisition strategy by adding new development assets tied to ENPP1 deficiency and skeletal health outcomes. The strategic acquisition is structured as an add on acquisition within healthcare M&A, with BioMarin Pharmaceutical acquisitions continuing as the company evaluates clinical data and plans next steps following Phase 3 readouts.